Resources by Therapeutic Area
January 29-31, 2014
San Diego, CA January 29-31, 2014 Booth #13 Registration at www.gtcbio.com
Single molecule measurements of tumor necrosis factor a and interleukin–6 in the plasma of patients with Crohn’s disease.
Journal of Immunological Methods | September 30, 2011
We applied a sensitive, single molecule detection technology to measure TNF–a and IL–6 in the plasma of patients with Crohn’s disease (CD), before and after treatment with anti–TNF–a therapy.
CAMBRIDGE, MA – August 19, 2011 – Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA™) technology, today announced results of a pilot study to measure biomarkers of inflammation from patients with Crohn’s d…
CAMBRIDGE, MA – November 2, 2010 – Quanterix Corporation, a single molecule technology company focused on developing a next generation diagnostics platform, announced today that it was awarded a total of $733,437 in grants under the Qualifying Therapeutic Discovery Project (QTDP) program. The QTDP p…